Effects of sulfaphenazole after collagenase-induced experimental intracerebral hemorrhage in rats

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 10, 2012, Pages 1849-1853

  Hama, Sayuri ^a   Ishihara, Yasuhiro ^b   Watanabe, Masatomo ^a   Danjo, Sonoko ^a,c   Nakamura, Yu ^c   Itoh, Kouichi ^a  

^a TOKUSHIMA BUNRI UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

Brain edema; Intracerebral hemorrhage; Magnetic resonance imaging; Rotation behavior; Striatum; Sulfaphenazole

Indexed keywords

COLLAGENASE; CYTOCHROME P450; REACTIVE OXYGEN METABOLITE; SULFAPHENAZOLE; SUPEROXIDE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN WATER; CIRCLING BEHAVIOR; CONTROLLED STUDY; ENZYME INHIBITION; LIPID PEROXIDATION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TREATMENT OUTCOME;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN EDEMA; CEREBRAL HEMORRHAGE; COLLAGENASES; DISEASE MODELS, ANIMAL; LIPID PEROXIDATION; MALE; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; SULFAPHENAZOLE; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84867272772     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b12-00525     Document Type: Article

References (17)

1. Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet, 373, 1632-1644 (2009).
2. Shinohara Y. Regional differences in incidence and management of stroke - Is there any difference between Western and Japanese guidelines on antiplatelet therapy? Cerebrovasc. Dis., 21 (Suppl. 1), 17-24 (2006).
3. Xi G, Keep RF, Hoff JT. Mechanisms of brain injury after intracerebral haemorrhage. Lancet Neurol., 5, 53-63 (2006).
4. MacLellan CL, Silasi G, Auriat AM, Colbourne F. Rodent models of intracerebral hemorrhage. Stroke, 41, S95-S98 (2010).
5. Rosenberg GA, Mun-Bryce S, Wesley M, Kornfeld M. Collagenase-induced intracerebral hemorrhage in rats. Stroke, 21, 801-807 (1990).
6. Aronowski J, Zhao X. Molecular pathophysiology of cerebral hemorrhage: secondary brain injury. Stroke, 42, 1781-1786 (2011).
7. Nakamura T, Kuroda Y, Yamashita S, Zhang X, Miyamoto O, Tamiya T, Nagao S, Xi G, Keep RF, Itano T. Edaravone attenuates brain edema and neurologic deficits in a rat model of acute intracerebral hemorrhage. Stroke, 39, 463-469 (2008).
8. Wu H, Wu T, Xu X, Wang J, Wang J. Iron toxicity in mice with col-lagenase- induced intracerebral hemorrhage. J. Cereb. Blood Flow Metab., 31, 1243-1250 (2011).
9. Gaasch JA, Lockman PR, Geldenhuys WJ, Allen DD, Van der Schyf CJ. Brain iron toxicity: differential responses of astrocytes, neurons, and endothelial cells. Neurochem. Res., 32, 1196-1208 (2007).
10. Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G. Deferoxamine-induced attenuation of brain edema and neurological deficits in a rat model of intracerebral hemorrhage. J. Neurosurg., 100, 672-678 (2004).
11. Zangar RC, Davydov DR, Verma S. Mechanisms that regulate production of reactive oxygen species by cytochrome P450. Toxicol. Appl. Pharmacol., 199, 316-331 (2004).
12. Ishihara Y, Sekine M, Nakazawa M, Shimamoto N. Suppression of myocardial ischemia-reperfusion injury by inhibitors of cytochrome P450 in rats. Eur. J. Pharmacol., 611, 64-71 (2009).
13. Ishihara Y, Sekine M, Hamaguchi A, Kobayashi Y, Harayama T, Nakazawa M, Shimamoto N. Effects of sulfaphenazole derivatives on cardiac ischemia-reperfusion injury: association of cytochrome P450 activity and infarct size. J. Pharmacol. Sci., 113, 335-342 (2010).
14. McFayden MC, Melvin WT, Murray GI. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem. Pharmacol., 55, 825-830 (1998).
15. Chat M, Bayol-Denizot C, Suleman G, Roux F, Minn A. Drug metabolizing enzyme activities and superoxide formation in primary and immortalized rat brain endothelial cells. Life Sci., 62, 151-163 (1998).
16. Khan M, Mohan IK, Kutala VK, Kumbala D, Kuppusamy P. Cardioprotection by sulfaphenazole, a cytochrome P450 inhibitor: mitigation of ischemia-reperfusion injury by scavenging of reactive oxygen species. J. Pharmacol. Exp. Ther., 323, 813-821 (2007).
17. Mancy A, Dijols S, Poli S, Guengerich FP, Mansuy D. Interaction of Sulfaphenazole derivatives with human liver cytochromes P450 2C: Molecular origin of the specific inhibitory effects of sulfaphenazole on CYP2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry, 35, 16205-16212 (1996).